1. A method of treating or preventing cancer, comprising administering to a patient an antibody having the ability to bind to CLDN18.2, in combination with an agent that stabilizes or enhances the expression of CLDN18.2.2. The method of claim 1, wherein CLDN18.2 expression is observed on the cell surface of cancer cells. The method of claim 1 or 2, wherein the agent stabilizing or enhancing the expression of CLDN18.2 comprises a preparation that causes cell cycle arrest or cell accumulation in one or more phases of the cell cycle, preferably in one or more phases of the cell cycle other than G1 -phases, more preferably in the G2 phase and / or S phase. 4. A method according to claim 1 or 2, wherein the agent stabilizing or increasing the expression of CLDN18.2 comprises a preparation selected from the group consisting of anthracyclines, platinum compounds, nucleoside analogs, taxanes and camptothecin analogues or prodrugs thereof, and combinations thereof. The method of claim 1 or 2, wherein the agent stabilizing or enhancing the expression of CLDN18.2 includes a drug selected from the group consisting of epirubicin, oxaliplatin, cisplatin, 5-fluorouracil or its prodrugs, docetaxel, irinotecan and combinations thereof. . The method of claim 1 or 2, wherein the agent stabilizing or increasing the expression of CLDN18.2 comprises a combination of oxaliplatin and 5-fluorouracil or its prodrugs, a combination of cisplatin and 5-fluorouracil or its prodrugs, a combination of at least one anthracycline and oxaliplatin, a combination of at least one anthracycline and cisplatin, a combination of at least one anthracycline and 5-fluorouracil or its prodrugs, a combination of at least one taxane and oxaliplatin1. Способ лечения или предотвращения раковых заболеваний, включающий введение пациенту антитела, обладающего способностью связываться с CLDN18.2, в комбинации со средством, стабилизирующим или увеличивающим экспрессию CLDN18.2.2. Способ по п. 1, согласно которому экспре
